Regeneron Pharmaceuticals develops and markets antibody medicines discovered using its proprietary VelociSuite platforms for fully human biologics. Core products target serious eye diseases and inflammatory conditions, with a pipeline addressing cancer, cardiovascular, and other therapeutic areas. The company integrates research, clinical development, manufacturing, and commercialization within a single organization.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 3,028.7 | — | 808.7 | -22.9% |
| Q2 2025 | 3,675.6 | — | 1,391.6 | 7.4% |
| Q3 2025 | 3,754.3 | — | 1,460 | 6.3% |
| Q4 2025 | 3,884.3 | — | 844.6 | -36.9% |
| Q1 2026 | 3,605.4 | 19% | 727.2 | -10.1% |
| Q2 2026 | 4,290.7 | 16.7% | 1,296.9 | -6.8% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: NetEase, Inc. (NTES), Comcast Corporation (CMCSA), Warner Bros. Discovery, Inc. (WBD), Ross Stores, Inc. (ROST), Lumentum Holdings Inc. (LITE), O'Reilly Automotive, Inc. (ORLY)